Recent Trends of Infectious Complications Following Heart Transplantation.
Adult
Anti-Bacterial Agents
/ administration & dosage
Antibiotic Prophylaxis
Antifungal Agents
/ administration & dosage
Antiviral Agents
/ administration & dosage
Bacterial Infections
/ epidemiology
California
/ epidemiology
Female
Heart Transplantation
/ adverse effects
Humans
Immunocompromised Host
Immunosuppressive Agents
/ adverse effects
Male
Middle Aged
Mycoses
/ epidemiology
Opportunistic Infections
/ epidemiology
Protective Factors
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Virus Diseases
/ epidemiology
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
16
5
2020
medline:
9
2
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
Heart transplantation is a life-saving procedure that has seen improvements in transplant and patient outcomes due to advances in immunosuppression and prevention of posttransplantation infectious episodes (IEps). This study systematically evaluates IEps in the modern era of heart transplantation at Stanford University Medical Center. This is a single-center retrospective review that includes 279 consecutive adult heart transplantation recipients from January 2008 to September 2017. Baseline demographic, clinical, serological, and outcomes information were collected. Kaplan-Meier estimator was used to assess survival stratified by IEp occurrence within the first year. A total of 600 IEps occurred in 279 patients (2.15 IEps per patient) during a median follow-up period of 3 years. Overall survival was 83.3% (95% confidence interval [CI], 76.2-88.4) at 1 year posttransplantation for those with any IEp compared with 93.0% (95% CI, 87.2-96.4) in those without IEp (P = 0.07). Bacterial IEps were the most common (n = 375; 62.5%), followed by viral (n = 180; 30.0%), fungal (n = 40; 6.7%), and parasitic (n = 5; 0.8%). IEps by Gram-negative bacteria (n = 210) outnumbered those by Gram-positive bacteria (n = 142). Compared with prior studies from our center, there was a decreased proportion of viral (including cytomegalovirus), fungal (including Aspergillus spp. and non-Aspergillus spp. molds), and Nocardia infections. There were no IEps due to Mycobacterium tuberculosis, Pneumocystis jirovecii, or Toxoplasma gondii. A significant reduction in viral, fungal, and Nocardia IEps after heart transplantation was observed, most likely due to advancements in immunosuppression and preventive strategies, including pretransplant infectious diseases screening and antimicrobial prophylaxis.
Sections du résumé
BACKGROUND
Heart transplantation is a life-saving procedure that has seen improvements in transplant and patient outcomes due to advances in immunosuppression and prevention of posttransplantation infectious episodes (IEps). This study systematically evaluates IEps in the modern era of heart transplantation at Stanford University Medical Center.
METHODS
This is a single-center retrospective review that includes 279 consecutive adult heart transplantation recipients from January 2008 to September 2017. Baseline demographic, clinical, serological, and outcomes information were collected. Kaplan-Meier estimator was used to assess survival stratified by IEp occurrence within the first year.
RESULTS
A total of 600 IEps occurred in 279 patients (2.15 IEps per patient) during a median follow-up period of 3 years. Overall survival was 83.3% (95% confidence interval [CI], 76.2-88.4) at 1 year posttransplantation for those with any IEp compared with 93.0% (95% CI, 87.2-96.4) in those without IEp (P = 0.07). Bacterial IEps were the most common (n = 375; 62.5%), followed by viral (n = 180; 30.0%), fungal (n = 40; 6.7%), and parasitic (n = 5; 0.8%). IEps by Gram-negative bacteria (n = 210) outnumbered those by Gram-positive bacteria (n = 142). Compared with prior studies from our center, there was a decreased proportion of viral (including cytomegalovirus), fungal (including Aspergillus spp. and non-Aspergillus spp. molds), and Nocardia infections. There were no IEps due to Mycobacterium tuberculosis, Pneumocystis jirovecii, or Toxoplasma gondii.
CONCLUSIONS
A significant reduction in viral, fungal, and Nocardia IEps after heart transplantation was observed, most likely due to advancements in immunosuppression and preventive strategies, including pretransplant infectious diseases screening and antimicrobial prophylaxis.
Identifiants
pubmed: 32413012
doi: 10.1097/TP.0000000000003307
pii: 00007890-202010000-00032
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antifungal Agents
0
Antiviral Agents
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e284-e294Références
Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357:2601–2614
Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis. 2001; 33:629–640
Haddad F, Deuse T, Pham M, et al. Changing trends in infectious disease in heart transplantation. J Heart Lung Transplant. 2010; 29:306–315
Khush KK, Cherikh WS, Chambers DC, et al.; International Society for Heart and Lung Transplantation. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-fifth adult heart transplantation report-2018; focus theme: multiorgan transplantation. J Heart Lung Transplant. 2018; 37:1155–1168
Stinson EB, Bieber CP, Griepp RB, et al. Infectious complications after cardiac transplantation in man. Ann Intern Med. 1971; 74:22–36
Nelson JK, Giraldeau G, Montoya JG, et al. Donor-derived coccidioides immitis endocarditis and disseminated infection in the setting of solid organ transplantation. Open Forum Infect Dis. 2016; 3:ofw086
Stehlik J, Kobashigawa J, Hunt SA, et al. Honoring 50 years of clinical heart transplantation in circulation: in-depth state-of-the-art review. Circulation. 2018; 137:71–87
Potena L, Zuckermann A, Barberini F, et al. Complications of cardiac transplantation. Curr Cardiol Rep. 2018; 20:73
Kritikos A, Manuel O. Bloodstream infections after solid-organ transplantation. Virulence. 2016; 7:329–340
Oriol I, Sabé N, Simonetti AF, et al. Changing trends in the aetiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study. Transpl Int. 2017; 30:903–913
McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018; 66:e1–e48
Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis. 2019; 68:1611–1615
Goldman JD, Julian K. Urinary tract infections in solid organ transplant recipients: guidelines from the American Society of transplantation infectious diseases community of practice. Clin Transplant. 2019; 33:e13507
Kotton CN. Migrating from universal to personalized prevention: predicting the risk of cytomegalovirus infection after organ transplantation. Transplantation. 2018; 102:1787–1788